No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
www.ucb.comNo one on the platform currently holds UCB.BR.
No tracked institution reports a position in UCB.BR as of their last filing.
No one on the platform has traded UCB.BR yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.2% | 7.5% | 9.4% | — | — | — |
| Rev. Growth % | 25.8% | 7.7% | ||||
| Profit Margin % | 20.1% | 14.0% | 14.6% | |||
| Free Cash Flow Margin % | 24.3% | 15.4% | 14.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $8.7B | +14.1% | $11.59 | $10.54–$12.09 | — | 16 |
| 2027 | $9.6B | +10.5% | $13.59 | $12.85–$16.71 | — | 16 |
| 2028 | $10.7B | +11.1% | $16.21 | $13.59–$20.88 | — | 13 |
| 2029 | $11.7B | +9.4% | $19.44 | $18.11–$21.37 | — | 10 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $5.03 | $6.77 | +34.6% |
| 2026-02-26 | $4.95 | $6.44 | +30.1% |
| 2025-07-31 | $3.36 | $3.59 | +6.8% |
| 2025-02-27 | $2.58 | $2.85 | +10.5% |
| 2024-07-25 | $1.74 | $2.06 | +18.4% |
| 2024-04-25 | $1.36 | $1.58 | +16.2% |
| 2023-07-27 | $1.69 | $2.63 | +55.6% |
| 2023-02-22 | $0.76 |
| $1.22 |
| +61.6% |
| $12M |
| — |
| FAGR.BRFagron N.V. | $21.75 | +2.84% | $1.6B | — |
| HYL.BRHyloris Pharmaceuticals S.A. | $4.24 | +0.95% | $119M | — |
Source: Financial Modeling Prep · peers by sector/industry